001     307463
005     20251231120305.0
024 7 _ |a 10.1016/j.jaci.2025.12.993
|2 doi
024 7 _ |a pmid:41453450
|2 pmid
024 7 _ |a 0091-6749
|2 ISSN
024 7 _ |a 1085-8725
|2 ISSN
024 7 _ |a 1097-6825
|2 ISSN
037 _ _ |a DKFZ-2025-03062
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Grün, Sarah
|b 0
245 _ _ |a Somatic STAT5BN642H mutations shape variable immune landscapes resulting in heterogenous immune diseases.
260 _ _ |a Amsterdam [u.a.]
|c 2025
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1767095834_1386405
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a epub
520 _ _ |a Inborn errors of immunity (IEI) are traditionally understood as monogenic germline disorders. However, somatic mosaicism can also result in immune-mediated diseases, mimicking IEI. While early postzygotic mosaicism is the predominant mechanism, genetic variants causing a selective advantage to hematopoietic progenitors and/or mature immune cells may cause immune dysregulation and initiate disease at any age. Somatic mosaicism for STAT5BN642H was linked to severe allergic disease in infancy but its full clinical spectrum and underlying mechanisms remain incompletely defined.To elucidate how somatic N642H mutations of the STAT5B gene shape lineage-specific mosaicism, immune cell function and clinical phenotypes.We investigated three new patients - including one adult - with STAT5BN642H mosaicism using deep sequencing, flow and mass cytometry, and functional immune assays. Mutant cell distribution was mapped across blood lineages. A mouse model with mosaic STAT5BN642H mutation in hematopoietic stem cells was generated to study clonal dynamics and immune phenotypes.Patients displayed variable lineage mosaicism correlating with two predominant clinical outcomes: early-onset severe atopy with hypereosinophilia, and autoimmune-lymphoproliferative immunodeficiency with expansions of CD8 and γδ T cells. Functional studies revealed enhanced IL-2-mediated proliferation, effector differentiation, and oligoclonal T cell expansions. In mice, a few mutant HSCs reproduced the patient lineage-skewed immune landscapes with variable growth advantage of mutant cells across hematopoietic development and recapitulated patient T cell phenotypes. Targeted mTOR inhibition successfully controlled lymphoproliferation in patients.Our findings illuminate how a single somatic variant in few stem cells can remodel hematopoiesis, generating variable immune mosaics and heterogeneous immune disease.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Atopy
|2 Other
650 _ 7 |a Autoimmunity
|2 Other
650 _ 7 |a Clonal hematopoiesis
|2 Other
650 _ 7 |a Hematopoietic stem cells
|2 Other
650 _ 7 |a Immune dysregulation
|2 Other
650 _ 7 |a STAT5B
|2 Other
650 _ 7 |a Somatic mosaicism
|2 Other
650 _ 7 |a T cell lymphoproliferation
|2 Other
650 _ 7 |a mTOR inhibition
|2 Other
700 1 _ |a Rensing-Ehl, Anne
|b 1
700 1 _ |a Suske, Tobias
|b 2
700 1 _ |a Wolter-Mess, Julian
|b 3
700 1 _ |a Gehrig, Jonathan
|b 4
700 1 _ |a Mann, Jasmin
|b 5
700 1 _ |a König, Christoph
|b 6
700 1 _ |a Hauri, Mathias
|b 7
700 1 _ |a Heeg, Maximilian
|b 8
700 1 _ |a Leahy, Timothy Ronan
|b 9
700 1 _ |a Genevieve, David
|b 10
700 1 _ |a Gaillard, Jean-Baptiste
|b 11
700 1 _ |a Broly, Martin
|b 12
700 1 _ |a Bourdin, Arnaud
|b 13
700 1 _ |a Castro, Carla
|b 14
700 1 _ |a Seidel, Lea
|b 15
700 1 _ |a Bengsch, Bertram
|b 16
700 1 _ |a Aichele, Peter
|b 17
700 1 _ |a Weißert, Kristoffer
|b 18
700 1 _ |a Fernandez-Orth, Juncal
|b 19
700 1 _ |a Schipperges, Vincent
|b 20
700 1 _ |a Andrieux, Geoffroy
|b 21
700 1 _ |a Boerries, Melanie
|0 P:(DE-HGF)0
|b 22
700 1 _ |a Cabezas-Wallscheid, Nina
|b 23
700 1 _ |a Erlacher, Miriam
|b 24
700 1 _ |a Elling, Roland
|b 25
700 1 _ |a Speckmann, Carsten
|b 26
700 1 _ |a Heller, Lara
|b 27
700 1 _ |a Schulte, Björn
|b 28
700 1 _ |a Lorenz, Myriam
|b 29
700 1 _ |a Schwarz, Klaus
|b 30
700 1 _ |a Moriggl, Richard
|b 31
700 1 _ |a Ehl, Stephan
|b 32
773 _ _ |a 10.1016/j.jaci.2025.12.993
|g p. S0091674925021906
|0 PERI:(DE-600)2006613-2
|p nn
|t The journal of allergy and clinical immunology
|v nn
|y 2025
|x 0091-6749
909 C O |o oai:inrepo02.dkfz.de:307463
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 22
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2025
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-10
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J ALLERGY CLIN IMMUN : 2022
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-10
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-10
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b J ALLERGY CLIN IMMUN : 2022
|d 2024-12-10
920 1 _ |0 I:(DE-He78)FR01-20160331
|k FR01
|l DKTK Koordinierungsstelle Freiburg
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)FR01-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21